Exact Sciences Corporation (EXAS)
- Previous Close
59.48 - Open
54.50 - Bid 54.04 x 500
- Ask 54.20 x 200
- Day's Range
52.25 - 55.38 - 52 Week Range
52.25 - 100.77 - Volume
10,577,837 - Avg. Volume
2,663,317 - Market Cap (intraday)
9.992B - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-1.31 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
90.76
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
www.exactsciences.com6,500
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: EXAS
Performance Overview: EXAS
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXAS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXAS
Valuation Measures
Market Cap
9.99B
Enterprise Value
11.90B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.87
Price/Book (mrq)
3.19
Enterprise Value/Revenue
4.69
Enterprise Value/EBITDA
1.18k
Financial Highlights
Profitability and Income Statement
Profit Margin
-9.48%
Return on Assets (ttm)
-3.29%
Return on Equity (ttm)
-7.76%
Revenue (ttm)
2.53B
Net Income Avi to Common (ttm)
-240.23M
Diluted EPS (ttm)
-1.31
Balance Sheet and Cash Flow
Total Cash (mrq)
652.09M
Total Debt/Equity (mrq)
79.10%
Levered Free Cash Flow (ttm)
130.38M
Research Analysis: EXAS
Company Insights: EXAS
EXAS does not have Company Insights